10/19/2005 5:10:40 PM
International Wex Technologies Inc. (the "Company") is pleased to announce that it has received a Screening Acceptance Letter from Health Canada regarding a CTA filing for an open-label extension study of Tectin(TM) in patients with moderate to severe cancer-related pain. Approval for trial commencement is expected by April 9, 2004.
This study is a long-term continuation of the Phase IIb/III multicentre, double-blind, placebo-controlled trial. The purpose of the open-label trial is to make Tectin(TM) available to all patients who participate in the Phase IIb/III study, thereby allowing them to benefit from continued treatment while providing the company with data on the long-term safety and efficacy of the product.
comments powered by